BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23913880)

  • 1. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.
    Gamalo MA; Tiwari RC; LaVange LM
    Pharm Stat; 2014; 13(1):25-40. PubMed ID: 23913880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-inferiority and networks: inferring efficacy from a web of data.
    Lin J; Gamalo-Siebers M; Tiwari R
    Pharm Stat; 2016; 15(1):54-67. PubMed ID: 26639225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The network meta-analytic-predictive approach to non-inferiority trials.
    Schmidli H; Wandel S; Neuenschwander B
    Stat Methods Med Res; 2013 Apr; 22(2):219-40. PubMed ID: 22218367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
    Gordon Lan KK; Wittes JT
    Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian approach to non-inferiority trials for normal means.
    Gamalo MA; Wu R; Tiwari RC
    Stat Methods Med Res; 2016 Feb; 25(1):221-40. PubMed ID: 22619277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomes.
    Turner RM; Clements MN; Quartagno M; Cornelius V; Cro S; Ford D; Tweed CD; Walker AS; White IR
    Stat Med; 2023 Apr; 42(8):1127-1138. PubMed ID: 36661242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian non-inferiority approach using experts' margin elicitation - application to the monitoring of safety events.
    Aupiais C; Alberti C; Schmitz T; Baud O; Ursino M; Zohar S
    BMC Med Res Methodol; 2019 Sep; 19(1):187. PubMed ID: 31533631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and analysis of non-inferiority mortality trials in oncology.
    Rothmann M; Li N; Chen G; Chi GY; Temple R; Tsou HH
    Stat Med; 2003 Jan; 22(2):239-64. PubMed ID: 12520560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian approach for assessing non-inferiority in a three-arm trial with pre-specified margin.
    Ghosh S; Ghosh S; Tiwari RC
    Stat Med; 2016 Feb; 35(5):695-708. PubMed ID: 26434554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidential approach to non-inferiority clinical trials.
    Wang SJ; Blume JD
    Pharm Stat; 2011; 10(5):440-7. PubMed ID: 21928286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some practical considerations in three-arm non-inferiority trial design.
    Zhou M; Kundu S
    Pharm Stat; 2016 Nov; 15(6):550-559. PubMed ID: 27681603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
    Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
    Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues on the selection of non-inferiority margin in clinical trials.
    Hou Y; Wu XY; Li K
    Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.
    Li JX; Chen WC; Scott JA
    J Biopharm Stat; 2016; 26(6):1056-1066. PubMed ID: 27541990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.